Data show OXC-201 may be a promising treatment for allergic asthma.
A new study, Pharmacological OGG1 inhibition decreases murine allergic airway inflammation, was published 17[th] of October in Respiratory pharmacology, Frontiers in Pharmacology, (DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M and Egesten A) and demonstrates that Oxcia’s potential clinical candidate OXC-201 (TH5487) may be a promising treatment for allergic asthma.Allergic asthma is a complex inflammatory disease characterized by wheezing, dyspnea, coughing, chest tightness and variable airflow